



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|-----------------|-------------|----------------------|---------------------|------------------|
| 09/707,121 | 11/06/2000 | Brian Mathur | LEX-0083-USA | 8244 |

24231 7590 03/08/2002

LEXICON GENETICS INCORPORATED
8800 TECHNOLOGY FOREST PLACE
THE WOODLANDS, TX 77381-1160

EXAMINER

PAK, YONG D

| ART UNIT | PAPER NUMBER |
|----------|--------------|
|----------|--------------|

1652

DATE MAILED: 03/08/2002

13

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action

Application No.

09/707,121

Applicant(s)

MATHUR ET AL.

Examiner

Yong Pak

Art Unit

1652

--The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

THE REPLY FILED 06 February 2002 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.

PERIOD FOR REPLY [check either a) or b)]

- a) ☒ The period for reply expires 3 months from the mailing date of the final rejection.
- b) ☐ The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.
- ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).

Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

1. ☐ A Notice of Appeal was filed on _____. Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.
2. ☐ The proposed amendment(s) will not be entered because:
- (a) ☐ they raise new issues that would require further consideration and/or search (see NOTE below);
 - (b) ☐ they raise the issue of new matter (see Note below);
 - (c) ☐ they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or
 - (d) ☐ they present additional claims without canceling a corresponding number of finally rejected claims.

NOTE: _____.

3. ☐ Applicant's reply has overcome the following rejection(s): _____.
4. ☐ Newly proposed or amended claim(s) _____ would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).
5. ☐ The a) ☐ affidavit, b) ☐ exhibit, or c) ☐ request for reconsideration has been considered but does NOT place the application in condition for allowance because: _____.
6. ☐ The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly raised by the Examiner in the final rejection.
7. ☒ For purposes of Appeal, the proposed amendment(s) a) ☐ will not be entered or b) ☒ will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.

The status of the claim(s) is (or will be) as follows:

Claim(s) allowed: _____.

Claim(s) objected to: _____.

Claim(s) rejected: 2-4.

Claim(s) withdrawn from consideration: _____.

8. ☐ The proposed drawing correction filed on _____ is a) ☐ approved or b) ☐ disapproved by the Examiner.
9. ☐ Note the attached Information Disclosure Statement(s) (PTO-1449) Paper No(s). _____.
10. ☐ Other: _____

DETAILED ACTION

The amendment filed February 6, 2002, under 37 CFR 1.116, canceling claim 1, has been entered but is not deemed to place the application in condition for allowance.

Claims 2-4 are pending.

Response to Arguments

Applicant's arguments filed February 6, 2002, have been fully considered but they are not persuasive.

Claims 2-4 remain rejected under 35 U.S.C. 101 because the claimed invention lacks patentable utility.

Applicants argue that it is clear that SEQ ID NO:1 encodes a kinase because it is stated in the claims, specification and that one of ordinary skill in the art would recognize the invention as a kinase and that the utility of such a kinases is well established in the art and cites various U.S. Patents demonstrating utility of kinases. The examiner disagrees. Identifying a polynucleotide as encoding a kinase-like protein or proteins with structural similarity to a particular enzyme does not endow the polynucleotide with such a utility. The specification fails to provide objective evidence of any activity for the encoded proteins or to show that these proteins even exist. Applicant only states that the encoded protein sequence shares structural similarity with animal kinases, especially serine/threonine protein kinases (page 2, lines 2-5). Since the specification sets forth no specific function for the encoded protein, the claimed polynucleotides encode a protein with no ascribe function. Therefore, there is no

Art Unit: 1652

specific, substantial, or credible utility that is well known, apparent, or implied by the relationship of the instant polynucleotide to the polynucleotide encoding a kinase.

Claim Rejections - 35 USC § 112

Claims 2-4 remain rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

Since the claimed invention is not supported by either a specific asserted utility or a well established utility for the reasons set forth above, one skilled in the art clearly would not know how to use the claimed invention so that it would operate as intended without undue experimentation. In the state of the art, the function of a polynucleotide is unpredictable from its structure and the functionality of a polynucleotide must be known in order to use the polynucleotide. Therefore, the specification does not teach how to use polynucleotides with unknown function.

Claim 2 remains rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Applicants argue that hybridization conditions for oligonucleotides and polynucleotides are defined in the specification. The examiner disagrees. The condition defined in the specification is one example of a highly stringent condition since

Art Unit: 1652

the condition is preceded by "e.g." and not a definite highly stringent condition.

Therefore, since the exact hybridization condition is unclear, the scope of DNA molecules in claim 2 is unclear.

No claims are allowed.


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Yong Pak whose telephone number is 703-308-9363. The examiner can normally be reached on 8:00 A.M. to 4:30 P.M weekdays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapu Achutamurthy can be reached on 703-308-3804. The fax phone numbers for the organization where this application or proceeding is assigned are 703-872-9310 for regular communications and 703-746-7240 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Yong Pak
Patent Examiner

March 6, 2002



YONG PAK
PATENT EXAMINER
MAR 6 2002